Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 5Terminated 4Completed 4Withdrawn 3Recruiting 2Not yet recruiting 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 6Genitourinary 5Gastrointestinal 3Gynecologic 2Thoracic 1Sarcoma 1CNS 1

Conditions

Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 134pembrolizumab 113Pemetrexed 94Cisplatin 88durvalumab 62Paclitaxel 60osimertinib 54Nivolumab 54Docetaxel 44atezolizumab 41Etoposide 30Radiotherapy 28Radiosurgery 26Gemcitabine 26Specimen Handling 24Ipilimumab 23Taxes 19Magnetic Resonance Spectroscopy 19amivantamab 16130-nm albumin-bound paclitaxel 16Drug Therapy 15Bevacizumab 15Radiation 14Platinum 14Immunoglobulin G 14Disulfides 14cemiplimab 13Crizotinib 13Cyclophosphamide 12Biopsy 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Radiation Dose Hypofractionation × Thoracic × Clear all
NCT04310020 2026-05-13

Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer Patients

National Cancer Institute (NCI)

Phase 2 Active not recruiting
47 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡